FRES - Fresh2 Group Ltd
IEX Last Trade
1.13
-0.240 -21.239%
Share volume: 0
Last Updated: Mon 23 Dec 2024 02:30:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$1.37
-0.24
-17.52%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
0 0%
1 Month
-20.71%
3 Months
-42.18%
6 Months
136.11%
1 Year
7.36%
2 Year
-79.19%
Key data
Stock price
$1.13
DAY RANGE
$1.13 - $1.37
52 WEEK RANGE
$0.31 - $3.70
52 WEEK CHANGE
$7.94
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Haohan Xu
Region: US
Website: fresh2.co
Employees: 75
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: fresh2.co
Employees: 75
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Fresh2 Group Limited, a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests using cancer differentiation analysis technology and device to corporations and life insurance companies in the People's Republic of China. The company was formerly known as AnPac Bio-Medical Science Co., Ltd. and changed its name to Fresh2 Group Limited in April 2023. The company was incorporated in 2010 and is based in New York, New York.
Recent news